Novel bispecific antibody causes tumor regression in patients with non-Hodgkin lymphoma

被引：0
|
作者：
机构：
来源：
Nature Clinical Practice Oncology | 2008年 / 5卷 / 12期
关键词：
D O I：
10.1038/ncponc1245
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：684 / 684
相关论文
共 50 条
  • [1] Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment
    Allison M. Bock
    Grzegorz S. Nowakowski
    Yucai Wang
    Current Treatment Options in Oncology, 2022, 23 : 155 - 170
  • [2] Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment
    Bock, Allison M.
    Nowakowski, Grzegorz S.
    Wang, Yucai
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022, 23 (02) : 155 - 170
  • [3] Challenges in the development of bispecific antibodies for non-Hodgkin lymphoma
    Dickinson, Michael
    LANCET HAEMATOLOGY, 2022, 9 (05): : E314 - E315
  • [4] Preparing Nurses for CD20-CD3 Bispecific Antibody Treatment in Patients With Non-Hodgkin Lymphoma
    van der Linde, Sam
    Knights, Emily
    Robertson, Molly
    Krishnasamy, Meinir
    Minson, Adrian
    Dickinson, Michael
    CANCER NURSING, 2024,
  • [5] Antibody response to influenza vaccination in patients with non-Hodgkin lymphoma
    Centkowski, P
    Sawczuk-Chabin, J
    Brydak, L
    Machala, M
    Kalinka, E
    Blasinska-Morawiec, M
    Wegrzyn, J
    Skotnicki, A
    Federowicz, I
    Walewski, J
    Bilinski, P
    Warzocha, K
    ANNALS OF ONCOLOGY, 2005, 16 : 76 - 77
  • [6] NVG-111, a novel ROR1xCD3 bispecific antibody for non-Hodgkin lymphoma.
    Granger, David
    Gohil, Satyen
    Barbarulo, Alessandro
    Baccaro, Annalisa
    Muczynski, Vincent
    Chester, Kerry
    Germaschewski, Fiona
    Batten, Toby
    Brown, Kathryn
    Cook, Sarah
    O'Donovan, Kieran
    Jasani, Parag
    Nathwani, Amit C.
    Phillips, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Infectious agents as causes of non-Hodgkin lymphoma
    Engels, Eric A.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2007, 16 (03) : 401 - 404
  • [8] Complete regression of cardiac non-Hodgkin lymphoma
    Morillas, P
    Quiles, J
    Nuñez, D
    Senent, C
    Martínez, S
    Fernández, JA
    Bertomeu, V
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2006, 106 (03) : 426 - 427
  • [9] PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF THE BISPECIFIC T-CELL ENGAGER ANTIBODY BLINATUMOMAB IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA
    Hijazi, Y.
    Klinger, M.
    Schub, A.
    Wu, B.
    Zhu, M.
    Kufer, P.
    Wolf, A.
    Nagors-en, D.
    HAEMATOLOGICA, 2013, 98 : 131 - 131
  • [10] Antibody therapy for non-Hodgkin's lymphoma
    Ansell, SM
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2004, 6 (02) : 175 - 181
12345